Dr. Matranais the Founder of Ochsner’s Precision Cancer Therapies Program, the onlycomprehensive, dedicated cancer phase 1 clinical trials center between Houstonand Birmingham. As such, he has conducted numerous first-in-human studieswith novel agents (often first-in-class compounds), including dose-escalationand dose-expansion phase 1 clinical trials. Dr. Matrana is agenitourinary oncologist who has been principal investigator for a large numberof practice-changing and standard-of-care-defining clinical trials,particularly in the area of renal cell carcinoma. Currently in hisrole as Ochsner’s System Medical Director for Precision Medicine, Dr. Matranaserves as the principal investigator for a number of large genomics studiessuch as those aimed at defining the role of minimal residual disease monitoringin cancer recurrence monitoring and advanced cancer treatment responsemonitoring, as well as large trials examining the clinical utility ofmulti-cancer early detection and pharmacogenomics.
LSUSchool of Medicine in New Orleans
M.D., May 2006.
TulaneUniversity, New Orleans, LA
M.S. in Human Genetics, May 2002
TulaneUniversity, New Orleans, LA
MD Anderson Cancer Center, Houston, TX
“Chief Chief” Fellow (July 1, 2012– June 30, 2013)
MD AndersonCancer Center, Houston, TX
Chief Fellow forResident Medical Education (July 1, 2011 – June 30, 2012)
MD Anderson Cancer Center, Houston,TX
Fellow, Hematology and Oncology, (July 1, 2010 – June 30, 2013)
Selected for full funding under NIH T32
OchsnerClinic Foundation, New Orleans, LA
Chief Medical Resident/Staff Hospitalist, (July 1, 2009 – June 30, 2010)
OchsnerClinic Foundation, New Orleans, LA
InternalMedicine Internship and Residency, (July 1, 2006 – June 30, 2009)
Nivolumab VERSUS Cabozantinib as Second-Line Therapy in Patients With Advanced Renal Cell Carcinoma: A Real-World Comparison. Clinical Genitourinary Cancer. 20:285-295.
PREVALENCEOF GENETIC TESTING AND MUTATIONS IN METASTATIC PROSTATE CANCER IN REAL-WORLDPRACTICE AT A SINGLE INSTITUTION. Journalof Investigative Medicine. 70:673-674.
Aphase I dose escalation study of PRS-343, a HER2/4-1BB bispecific molecule, inpatients with HER2-positive malignancies. Annalsof Oncology. 31:S462-S463.
Immunecheckpoint inhibitor use in cancer patients with a pre-existing history ofautoimmune disorders. Journal of Clinical Oncology.
PCR-basedcomprehensive genomic profiling (PCR-CGP): Feasibility from > 20,000 tumortissue specimens (TTS) and predicted impact on actionable biomarkeridentification versus hybrid capture (H)CGP and plasma (P)-CGP.. Journal of Clinical Oncology.
A phase II trial of pembrolizumab in combination with cisplatin or carboplatinand etoposide in chemotherapy naive patients with metastatic or unresectablehigh-grade gastroenteropanncreatic or lung neuroendocrine carcinoma. Journal of Clinical Oncology.
Phase Ib clinical study of CBP501, cisplatin, and nivolumab administered everythree weeks in patients with advanced refractory tumors: Efficacy indose-escalation and expansion cohorts.. Journalof Clinical Oncology.
APhase II basket trial of dual anti-CTLA-4 and anti-PD-1 blockade in rare tumors(DART) S1609: The neuroendocrine cohort. CancerResearch.
Aphase I/II multicenter study of ABI-009 (nab-sirolimus) combined with FOLFOXand bevacizumab as first-line (1L) therapy in patients (pts) with metastaticcolorectal cancer (mCRC) with or without PTEN loss.. Journal of Clinical Oncology.
No-costnext generation sequencing of advanced cancer patients within the StrataPrecision Oncology Network supports clinical trial enrollment.. Journal of Clinical Oncology.
Keywords/Tags: Phase 1 clinical trial, early phase clinical trials, novel agents, targeted therapies, clinical cancer genetics, cancer genomics, precision medicine, genitourinary cancers, renal cell carcinoma
Link to website: https://www.ochsner.org/doctors/marc-matrana
